Analysis of volatile compounds in exhaled breath condensate in patients with severe pulmonary arterial hypertension

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Mansoor, J K ^a   Schelegle, Edward S ^b   Davis, Cristina E ^c   Walby, William F ^b   Zhao, Weixiang ^c   Aksenov, Alexander A ^c   Pasamontes, Alberto ^c   Figueroa, Jennifer ^b   Allen, Roblee ^d  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; VOLATILE AGENT; VOLATILE ORGANIC COMPOUND;

ADULT; AGED; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; MALE; MASS FRAGMENTOGRAPHY; MEAN ARTERIAL PRESSURE; PARTIAL LEAST SQUARES REGRESSION; PULMONARY HYPERTENSION; SENSITIVITY AND SPECIFICITY; SOLID PHASE MICROEXTRACTION; SYSTOLIC BLOOD PRESSURE; METABOLISM; REGRESSION ANALYSIS;

BREATH TESTS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYPERTENSION, PULMONARY; LEAST-SQUARES ANALYSIS; VOLATILE ORGANIC COMPOUNDS;

EID: 84899701813     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095331     Document Type: Article

References (32)

1. Alfaro MF, Walby WF, Adams WC, Schelegle ES (2007) Breath condensate levels of 8-isoprostane and leukotriene B4 after ozone inhalation are greater in sensitive versus nonsensitive subjects. Exp Lung Res 33:115-133. (Pubitemid 46897651)
2. Carpagnano GE, Resta O, Gelardi M, Spanevello A, Di Gioia G, et al. (2007) Exhaled inflammatory markers in aspirin-induced asthma syndrome. Am J Rhinology 21(5): 542-547. (Pubitemid 350099762)
3. Conrad DH, Goyette J, Thomas PS (2008) Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Int Med (suppl 1): 78-84. (Pubitemid 350295398)
4. Phillips M, Altorki N, Austin J, Cameron RB, Cataneo RN, et al. (2007) Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomarkers 3(2): 95-109. (Pubitemid 47103811)
5. O'Reilly P, Bailey W (2007) Clinical use of exhaled biomarkers in COPD. Int J Chron Obstr Pulm Dis 2: 403-408.
6. Phillips M, Cataneo RN, Condos R, Ring Erickson GA, Greenberg J, et al. (2007) Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis 87(1): 44-52. (Pubitemid 44960164)
7. Van Muylem A, Knoop C, Estenne M (2007) Early detection of chronic pulmonary allograft dysfunction by exhaled biomarkers. Am J Respir Crit Care Med 175(7): 731-736. (Pubitemid 46536490)
8. Phillips M, Cataneo RN, Ditkoff BA, Fisher P, Greenberg J, et al. (2006) Prediction of breast cancer using volatile biomarkers in the breath. Breast Cancer Res and Treat 99(1): 19-21. (Pubitemid 44168599)
9. Phillips M, Boehmer JP, Cataneo RN, Cheema T, Eisen HJ, et al. (2004) Prediction of heart transplant rejection with a breath test for markers of oxidative stress. Am J Cardio 94(12): 1593-1594. (Pubitemid 40268475)
10. Phillips M, Cataneo RN, Cheema T, Greenberg J (2004) Increased breath biomarkers of oxidative stress in diabetes mellitus. Clinica Chimica Acta 344(1-2): 189-194. (Pubitemid 38626154)
11. Phillips M, Cataneo RN, Greenberg J, Grodman R, Salazar M (2003) Breath markers of oxidative stress in patients with unstable angina. Heart Disease 5(2):95-99. (Pubitemid 36538664)
12. Mansoor JK, Morrissey BM, Walby WF, Yoneda KY, Juarez M, et al. (2005) L-arginine supplementation enhances exhaled NO, breath condensate VEGF, and headache at 4,342 m. High Alt Med Biol 6(4): 289-300. (Pubitemid 43137285)
13. American Thoracic Society (1999) Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children. Am. J. Respir Crit Care Med 160:2104-2117.
14. Molina M, Zhao W, Sankaran S, Schivo M, Kenyon NJ, et al. (2008) Design-of-experiment optimization of exhaled breath condensate analysis using a miniature differential mobility spectrometer (DMS). Analytica Chimica Acta 628:155-161.
15. Andrade L, Manolakos ES (2003) Signal backgound estimatin and baseline correction algorithms for accurate DNA sequencing. J VLSI Signal Process 35:229-243.
16. Zhao WX, Davis CE (2009) Autoregressive model based feature extraction method for time shifted chromatography data. Chemom Intell Lab Syst 96:252-257.
17. Zhao W, Morgan JT, Davis CE (2008) Gas chromatography data classification based on complex coefficients of an autoregressive model. J Sensors [serial online]. Available at: http://www.hindawi.com/journals/js/2008/262501/ via the Internet. Accessed 11 Feb 2011.
18. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, et al. (2013) Definitions and diagnosis of pulmonary hypertension. JACC 62:SupplD 42-50.
19. Windey K, De Preter V, Louat T, Schuit F, Herman J, et al. (2012) Modulation of protein fermentation does not affect fecal water toxicity: a randomized crossover study in healthy subjects. PLoS One [serial online]. Dec. 20.
20. Cikach F, Tonelli A, Barnes J, Paschke K, Newman J, et al. (2013) Breath analysis in pulmonary arterial hypertension. Chest [Epub ahead of print]. Available: http://journal.publications.chestnet.org/article.aspx?articleid= 1745983 via the internet. Accessed 22 Nov 2013.
21. Smith D, Spaněl P (2011) Ambient analysis of trace compounds in gaseous media by SIFT-MS. Analyst 36:2009-2032.
22. Kwak J, Petri G (2011) Volatile disease biomarkers in breath: a critique. Curr Pharm Biotechnol 12:1067-1074.
23. Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, et al. (2005) Decreased exhaled nitric oxide in pulmonary arterial hypertension. Am J Respir Crit Care Med 172:352-357. (Pubitemid 41026146)
24. Cremona G, Higenbottam T, Borland C, Mist B (1994) Mixed expired nitric oxide in primary pulmonary hypertension in relation to lung diffusion capacity. QJM 87:547-551. (Pubitemid 24289825)
25. Kaneko FT, Arroliga AC, Dweik RA, Comhair SA, Laskowski D, et al. (1998) Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 158:917-923. (Pubitemid 28449461)
26. Riley MS, Pórszász J, Miranda J, Engelen MP, Brundage B, et al. (1997) Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis. Chest 111:44-50. (Pubitemid 27043605)
27. Archer SL, Djaballah K, Humbert M, Weir KE, Fartoukh M, et al. (1998) Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 158:1061-1067. (Pubitemid 28489002)
28. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, et al. (1998) Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31:202-208. (Pubitemid 28064743)
29. Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, et al. (2004) Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 43:764-770. (Pubitemid 38296473)
30. Fijalkowsha A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, et al. (2006) Serum n-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129:1313-1321.
31. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, et al. (2001) Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865-870.
32. Droste AS, Rohde D, Voelkers M, Filush A, Bruckner T, et al. (2009) Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension. Respir Res 10:129-136.